These guidelines are intended to assist primary care physicians and other healthcare professionals in the management of infertility. This includes increasing awareness and educating about the scale of fertility problems, recognising the various causes of infertility, natural fecundity, and success rates of in vitro fertilisation (IVF) treatment in relation to female age. These guidelines also seek to establish clear referral criteria to guide primary care physicians.
Sexual intercourse every 2-3 days is recommended to optimise the chance of pregnancy; this is less stressful than timing intercourse to coincide with ovulation, which is not recommended unless in circumstances preventing regular intercourse (pg 22) . Grade D, Level 4 Women trying to get pregnant should be advised against excessive alcohol consumption of more than two drinks a day and episodes of binge drinking can cause fetal harm (pg 23).
Grade B, Level 2++
Men should be warned that excessive alcohol intake is detrimental to semen quality (pg 23).
Grade C, Level 2+
Women should be informed that smoking is likely to reduce their fertility (pg 23).
Grade B, Level 1+
Men who smoke should be informed that smoking is associated with reduced sperm parameters (pg 24).
Grade D, Level 4
Women trying to achieve a pregnancy should be informed that a body mass index (BMI) of 19-29 kg/m 2 is optimal (pg 24).
Grade B, Level 1+
Couples seeking treatment for infertility should be routinely screened for usage of long-term prescription medication, as some have been known to affect fertility (pg 25).
Grade B, Level 2++
Couples seeking treatment for infertility should also be routinely screened for occupational hazards and given appropriate advice (pg 25).
Grade C, Level 2+
Women intending to become pregnant should be informed that dietary supplementation with folic acid before conception and up to 12 weeks' gestation reduces the risk of having a baby with neural tube defects. The recommended dose is 0.4 mg per day. For women who have previously had an infant with a neural tube defect or who are receiving anti-epileptic medication, a higher dose of 5 mg per day is recommended (pg 25).
Grade A, Level 1++
Women who are concerned about their fertility should be offered rubella susceptibility screening so that those who are susceptible to rubella can be offered rubella vaccination and be advised not to become pregnant for at least one month following vaccination (pg 26).
GPP
To avoid delay in fertility treatment, a specific enquiry about the timing and result of the most recent cervical smear test should be made to women who are concerned about their fertility. Cervical screening should be offered in accordance with the national cervical screening programme guidance (pg 26).

Assessment and basic investigations of infertility (including referral)
Couples with fertility concerns should be interviewed separately as well as together, to bring out important history that a partner may want confidential from the other (pg 27).
Grade D, Level 4
At the initial consult, each couple should be assessed for factors that may optimise or contraindicate the planned pregnancy, possible underlying causes of infertility, and the impact of infertility on the individual and relationship (pg 27).
A detailed history-taking and clinical examination should be carried out for couples with fertility concerns (refer to Annex A for details) (pg 27).
Patients meeting these criteria should be referred to specialists:
• Women aged < 30 years who are unable to conceive after regular unprotected intercourse for two years without any known reproductive pathology.
• Women aged > 30 years who are unable to conceive after regular unprotected intercourse for one year without any known reproductive pathology.
• Patients with a known history of reproductive pathology, e.g. amenorrhoea, pelvic inflammatory diseases, endometriosis.
• Patients with a known history or reason for infertility. 
Use of basal body temperature charts and home ovulation kits alone to predict ovulation should not be recommended to patients with fertility problems, as these are not always reliable in predicting ovulation, and lead to unnecessary anxiety and stress for the patient (pg 29).
Women with infertility should be offered a blood test to measure mid-luteal serum progesterone levels (about seven days before the expected menstrual cycle). If cycles are irregular or prolonged, this test may need to be repeated again weekly thereafter until the next menstrual period (pg 29).
Grade B, Level 2++
Follicle-stimulating hormone (FSH) and luteinising hormone (LH) investigations should be done on day 2-3 of the menstrual cycle. Patients with high levels of gonadotrophins should be informed that they are likely to have reduced fertility (pg 29).
Grade B, Level 2+
Women with infertility should be offered screening for Chlamydia trachomatis before undergoing instrumentation (pg 29).
Grade B, Level 2++
If screening for Chlamydia trachomatis has not been carried out, prophylactic antibiotics should be given before uterine instrumentation (pg 29).
The result of semen analysis and assessment of ovulation should be completed before the clinician embarks on tubal assessment (pg 30).
GPP
Hysterosalpingography (HSG) should be used as the firstline investigation in tubal assessment (pg 30).
Grade B, Level 2++
Chlamydia antibody titre (CAT) should be considered as an alternative to HSG if the resources are available (pg 30).
Grade A, Level 1+
Laparoscopy and dye hydrotubation should be offered to women with comorbidities, such as pelvic inflammatory disease, previous ectopic pregnancy or endometriosis (pg 31).
Grade B, Level 2+
Fertiloscopy and transvaginal hydrolaparoscopy should not be offered routinely as an alternative to laparoscopy hydrotubation, as their diagnostic accuracy still requires further evaluation (pg 31).
Grade C, Level 3
When available, transvaginal ultrasound may be used as a screening test for the assessment of uterine cavity in subfertile women (pg 32).
Grade C, Level 2+
Operative hysteroscopy should not be offered as an initial investigation (pg 32). 
Grade B, Level 2++
Ovulatory dysfunction
Grade C, Level 2+
Where amenorrhoea (which occurs in women with functional hypothalamic pituitary failure) has occurred for longer than a year in duration, assessment of the bone mineral densities should be considered (pg 34).
When drug-induced anovulation is suspected, medications should be altered or discontinued, if possible. If the medication which causes anovulation cannot be altered or discontinued, referral to a reproductive medicine specialist for further management is indicated (pg 35).
GPP
Patients with anorexia nervosa should be referred to a mental health care provider for further management (pg 35).
Patients with organic lesions of the hypothalamus and pituitary gland should be referred to a reproductive specialist (pg 35).
Women should be told that premature ovarian failure is not a definitive diagnosis of infertility, as approximately 5%-10% of these women may conceive spontaneously and unexpectedly after the diagnosis (pg 36).
Grade C Level 2+
Women with spontaneous premature ovarian failure should be referred to an endocrinologist to investigate asymptomatic autoimmune adrenal insufficiency (pg 36).
Grade C, Level 3
Fertility options in women with premature ovarian failure include the use of an oocyte (egg) donor or embryo donor in an Assisted Reproductive Programme (ARP) (pg 36).
Grade C, Level 2+
Dopamine receptor agonists are the first-line treatment for patients with idiopathic hyperprolactinaemia secondary to pituitary adenoma (pg 36).
Grade A, Level 1+
Surgical transsphenoidal resection of microadenomas should not be the primary therapeutic approach for patients with hyperprolactinaemia secondary to pituitary adenoma (pg 37).
Grade C, Level 2+
Managing infertility in polycystic ovary syndrome (PCOS)
Diagnosis of polycystic ovary syndrome should only be made when other aetiologies have been excluded (thyroid dysfunction, congenital adrenal hyperplasia, hyperprolactinaemia, androgen secreting tumours and Cushing's syndrome) (pg 38).
Grade D, Level 4
The following investigations should be done to exclude other aetiologies before a diagnosis of polycystic ovary syndrome is made: Grade D, Level 4
The use of exogenous gonadotrophins is associated with increased chances of multiple pregnancy, and therefore, intense monitoring of ovarian response is required (pg 42).
GPP
Laparoscopic ovarian surgery alone is usually effective in < 50% of women, and additional ovulation induction medication is required under those circumstances (pg 42).
Grade B, Level 2++
Low-dose therapy with gonadotrophin is recommended, as it offers a significantly lower risk of ovarian hyperstimulation in women with polycystic ovary syndrome (pg 42).
The recommended third-line treatment for infertility in women with polycystic ovary syndrome is in vitro fertilisation (pg 42).
Grade C, Level 2+
As aromatase inhibitors are currently not licensed for use as ovulation induction, we do not recommend the clinical use of aromatase inhibitors for routine ovulation induction (pg 43).
GPP
The routine use of metformin in ovulation induction is not recommended as monotherapy or in combination with clomiphene citrate (pg 43).
Grade D, Level 3
There is currently insufficient evidence to suggest improvement in live birth rates on treatment with metformin before or during assisted reproductive technique cycles, and its routine use is not recommended (pg 43).
Grade B, Level 2+
The combined use of metformin and clomiphene citrate is recommended for women with clomiphene resistance, especially if they are obese (BMI > 27.5 kg/m 2 ) (pg 44).
Grade A, Level 1+
There is insufficient evidence to recommend the widespread use of metformin in pregnant women with polycystic ovary syndrome (pg 45 
Grade B, Level 1+
Male infertility
Both male and female partners should be investigated concurrently for couples who present for infertility assessment (pg 50).
GPP
Semen analysis should be done as the primary investigation for male infertility (see section 4) (pg 50).
Grade B, Level 2+
Hormonal investigations for male infertility should be limited to FSH, LH and testosterone levels (pg 50).
GPP
Karyotyping and Y microdeletion test should be considered for men with nonobstructive azoospermia (pg 51).
Grade D, Level 3
Referral to a tertiary centre should be made for: 
GPP
General advice, such as cessation of smoking, steroid use and withdrawal of offensive medication could be given at primary setting (pg 51).
Couples trying to conceive should generally avoid exposure to harmful chemicals (e.g. by wearing protective clothing when appropriate to reduce the risk of exposure to harmful chemicals) (pg 51).
Antioxidant supplementation for subfertile males may be used to improve live birth and pregnancy rates for subfertile couples (pg 52).
Grade A, Level 1+
Referral to a fertility specialist should be facilitated if the female is over 35 years old (pg 52).
GPP
Varicocele treatment may be considered when the female evaluation is normal and the man has a palpable varicocele with suboptimal semen quality (pg 52).
Grade B, Level 2++
In azoospermia, spermatozoa may be retrieved from the testis/epididymis using a variety of techniques such 
Tubal-infertility (preventive strategies & treatment)
Women with high risk profiles (early sexual debut, multiple partners, noncompliance with safe sexual advice, etc.)
should be screened for Chlamydia trachomatis in their urogenital tracts and be promptly treated to prevent future repercussions, including tubal infertility (pg 58).
Grade C, Level 2+
Partners of Chlamydia-positive women should be tested and treated to prevent reinfection of the treated women.
Positive cases should be referred to the Department of STI Control for contact tracing and treatment (pg 58).
Oral doxycycline (100 mg twice daily for 7-14 days) and
azithromycin ( 
